Validity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16)

被引:0
|
作者
Clarke, Nathan A. [1 ]
Wong, Brendon [2 ]
Lawrance, Rachael [1 ]
Ingelgard, Anders [2 ]
Griebsch, Ingolf [2 ]
Cella, David [3 ]
Trigg, Andrew [1 ]
机构
[1] Adelphi Mill, Adelphi Values, Bollington SK10 5JB, Cheshire, England
[2] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[3] Northwestern Univ, Chicago, IL USA
关键词
Advanced breast cancer; NFBSI-16; Psychometric; Meaningful change; Minimal important difference; Patient-reported outcomes; Patient experience data; INTERPRETING CHANGE; HEALTH;
D O I
10.1186/s41687-024-00776-y
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BackgroundBreast cancer is one of the most common cancers in women. Patient-reported outcome measures are used to evaluate patients' health-related quality of life in clinical breast cancer studies. This study evaluated the structure, validity, reliability, and responsiveness of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) subscales in a clinical trial featuring patients with advanced/metastatic breast cancer (aBC), and estimated NFBSI-16 meaningful change thresholds.MethodsData from 101 patients with aBC enrolled in a phase II trial (Xenera-1) were included for psychometric evaluation of the NFBSI-16. Subscale structure was evaluated by assessing inter-item correlations, item-total correlations, and internal consistency (cycles 2 and 5). Validity was assessed using scale-level convergent validity (cycles 2 and 5) and known-groups (Baseline). Reliability was analysed via test-retest at cycles 3-4, and responsiveness to improvement and worsening was evaluated at cycles 5, 7, and 9. Meaningful change thresholds were estimated using anchor-based methods (supported by distribution-based methods) at cycles 5, 7, and 9.ResultsNFBSI-16 internal consistency was acceptable, but item-total correlations suggested that its subscales and the GP5 item (side-effect of treatment) scores may be preferred over a total score. Convergent and known-groups evidence supported NFBSI-16 validity. Test-retest reliability was good to excellent for Total and DRS-P (disease-related symptoms: physical) scales, and moderate for the GP5 item. Responsiveness to worsening was generally demonstrated, but responsiveness to improvement could not be demonstrated due to limited observed improvement. Anchor-based meaningful change thresholds were estimated for DRS-P and Total scores.ConclusionThis study provides evidence that the NFBSI-16 has desirable psychometric properties for use in clinical studies in aBC. It also provides estimates of group- and individual-level meaningful change thresholds to facilitate score interpretation in future aBC research.
引用
收藏
页数:11
相关论文
共 18 条
  • [1] Priority Symptoms in Advanced Breast Cancer: Development and Initial Validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16)
    Garcia, Sofia F.
    Rosenbloom, Sarah K.
    Beaumont, Jennifer L.
    Merkel, Douglas
    Von Roenn, Jamie H.
    Rao, Deepa
    Cella, David
    [J]. VALUE IN HEALTH, 2012, 15 (01) : 183 - 190
  • [2] Comparative Analysis of Paper-Based and Web-Based Versions of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) Questionnaire in Breast Cancer Patients: Randomized Crossover Study
    Ma, Jinfei
    Zou, Zihao
    Pazo, Emmanuel Eric
    Moutari, Salissou
    Liu, Ye
    Jin, Feng
    [J]. JMIR MEDICAL INFORMATICS, 2021, 9 (03)
  • [3] Content validity of the National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy - Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients
    Krohe, Meaghan
    Tang, Derek H.
    Klooster, Brittany
    Revicki, Dennis
    Galipeau, Nina
    Cella, David
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2019, 17 (1)
  • [4] Content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form with advanced breast cancer patients
    Meaghan Krohe
    Derek H. Tang
    Brittany Klooster
    Dennis Revicki
    Nina Galipeau
    David Cella
    [J]. Health and Quality of Life Outcomes, 17
  • [5] Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)
    Kathleen J. Yost
    Susan E. Yount
    David T. Eton
    Cheryl Silberman
    Anne Broughton-Heyes
    David Cella
    [J]. Breast Cancer Research and Treatment, 2005, 90 : 295 - 298
  • [6] Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)
    Yost, KJ
    Yount, SE
    Eton, DT
    Silberman, C
    Broughton-Heyes, A
    Cella, D
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 90 (03) : 295 - 298
  • [7] Psychometric evaluation of the Functional Assessment of Cancer Therapy-Breast Symptom Index
    Revicki, Dennis A.
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2012, 1 (03) : 205 - 206
  • [8] The Validation of Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI) Among Iranian Women with Breast Cancer
    Zamanian, Hadi
    Daryaafzoon, Mona
    Amini-Tehrani, Mohammadali
    Taheri-Kharameh, Zahra
    Foroozanfar, Sahar
    [J]. INTERNATIONAL JOURNAL OF CANCER MANAGEMENT, 2020, 13 (03)
  • [9] Face Validity of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FACT-B) into Formal Arabic
    Kobeissi, Loulou
    Abou Saad, Maya
    Doumit, Myrna
    Mohsen, Raed
    Salem, Ziad
    Tfayli, Arafat
    [J]. MIDDLE EAST JOURNAL OF CANCER, 2014, 5 (03) : 151 - 165
  • [10] Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument
    Brady, MJ
    Cella, DF
    Mo, F
    Bonomi, AE
    Tulsky, DS
    Lloyd, SR
    Deasy, S
    Cobleigh, M
    Shiomoto, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 974 - 986